We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Abbott Showcases Next-Generation Alinity Family of Systems at AACC 2020 Virtual Event

By LabMedica International staff writers
Posted on 15 Dec 2020
Print article
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Image: Alinity Family of Systems (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) showcased leading-edge technology at its virtual booth at 2020 AACC Annual Scientific Meeting with demonstrations of the company’s innovative systems, automation and informatics.

At the all virtual 2020 AACC held on December 13-17, Abbott demonstrated its next-generation Alinity family of systems across key laboratory disciplines designed to simplify diagnostics and help deliver results that drive better patient outcomes. Attendees to Abbott’s virtual booth experienced the company’s Alinity ci-series integrated clinical chemistry and immunoassay system, the Alinity h-series integrated hematology system and the Alinity m molecular system.

The Alinity series helps to easily adapt to the unpredictability of changing laboratory volume with scalable systems and multiple track connectivity options across Alinity platforms. The flexible, scalable systems allow easy addition of modules as lab volume grows over time, without having to replace any system. And with open automation and IT connectivity options such as Instrument Manager and AlinIQ BIS, a personalized solution can be designed for the entire laboratory. All this helps labs respond to the changing needs of the market and the community.

Alinity leverages powerful technology to redefine and improve operational productivity in the laboratory. Alinity allows users to more efficiently and effectively address limited space and increasing demand in their laboratory. Alinity has been designed to maximize the throughput in a more compact footprint. Additionally, Alinity allows staff more walkaway time, so they can focus on other critical tasks.

Alinity helps labs continually provide consistent, high-quality service and results through error-proof design elements and proven technology that minimize the frustration of repeat testing, system downtime, and medical errors. Additionally, labs can rely on Abbott’s high-quality assays with proven technology harmonized to CLSI guidelines, ensuring clear performance parameter definitions. And with predictive system monitoring through AlinIQ Always On, Abbott’s professional services can proactively monitor the health of the systems and help labs avoid unexpected downtime.


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.